Alnylam Pharma (ALNY) Tops Q4 EPS by 6c, Misses on Revenue; Offers FY26 Revenue Guidance
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $239.56 -2.42%
Revenue Growth %: +15.3%
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +15.3%
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of $1.25, $0.06 better than the analyst estimate of $1.19. Revenue for the quarter came in at $1.1 billion versus the consensus estimate of $1.15 billion.
GUIDANCE:
Alnylam Pharma sees FY2026 revenue of $4.9-5.3 billion, versus the consensus of $5.55 billion.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- U.S. and Denmark close in on a Greenland deal - Reuters
- Fold Holdings (FLD) files for 51.23M share offering by selling stockholders
- First Carolina Financial Services CFO to retire in January 2027
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
